naltrexone has been researched along with clomipramine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Insel, TR; Winslow, JT | 1 |
| Aulakh, CS; Benkelfat, C; Bykov, V; De Costa, BR; Rice, KC; Rothman, RB | 1 |
| Mendez, M; Miranda, HF; Pinardi, G; Sierralta, F | 1 |
| Campbell, M; Cueva, JE; Hallin, A; Schopler, E | 1 |
| Amiaz, R; Fostick, L; Gershon, A; Zohar, J | 1 |
| Gormez, A; Rana, F; Varghese, S | 2 |
| Amos, T; Chamberlain, SR; Fineberg, N; Ipser, JC; Rothbart, R; Siegfried, N; Stein, DJ | 1 |
6 review(s) available for naltrexone and clomipramine
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of autistic disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Clomipramine; Clonidine; Fenfluramine; Humans; Naltrexone; Rehabilitation, Vocational; Selective Serotonin Reuptake Inhibitors; Speech Therapy | 1996 |
Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Controlled Clinical Trials as Topic; Humans; Intellectual Disability; Naltrexone; Narcotic Antagonists; Self-Injurious Behavior | 2013 |
Pharmacotherapy for trichotillomania.
Topics: Acetylcysteine; Adult; Benzodiazepines; Clomipramine; Humans; Naltrexone; Olanzapine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trichotillomania | 2013 |
Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities: Abridged republication of a Cochrane systematic review.
Topics: Clomipramine; Humans; Intellectual Disability; Naltrexone; Narcotic Antagonists; Persons with Mental Disabilities; Risk Factors; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Treatment Outcome | 2014 |
1 trial(s) available for naltrexone and clomipramine
| Article | Year |
|---|---|
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
Topics: Adolescent; Adult; Aged; Clomipramine; Cross-Over Studies; Double-Blind Method; Drug Synergism; Female; Humans; Male; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2008 |
12 other study(ies) available for naltrexone and clomipramine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Serotonergic and catecholaminergic reuptake inhibitors have opposite effects on the ultrasonic isolation calls of rat pups.
Topics: Animals; Body Temperature; Catecholamines; Citalopram; Clomipramine; Desipramine; Flumazenil; Mazindol; Motor Activity; Naltrexone; Nortriptyline; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Serotonin Antagonists; Stress, Psychological; Ultrasonics; Vocalization, Animal | 1990 |
Apparent down-regulation of rat brain mu- and kappa-opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine.
Topics: Animals; Brain Chemistry; Clomipramine; Down-Regulation; Kinetics; Male; Naltrexone; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1989 |
Interaction of opioids with antidepressant-induced antinociception.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clomipramine; Drug Combinations; Female; Imipramine; Male; Maprotiline; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Pain Measurement; Random Allocation; Selective Serotonin Reuptake Inhibitors; Zimeldine | 1995 |